Efficacy of CAR19-22 with NKTR-255
| . | CAR19-22 + NKTR-255 (n = 9) . | CAR19-22 control (n = 8) . |
|---|---|---|
| CR/CRi | 8 (89%) | 7 (88%) |
| MRD-negative | 8 (89%) | 6 (75%) |
| Progression/relapse | 3 (33%) | 5 (62%) |
| Consolidative HCT | 2 (23%) | 1 (13%) |
| 6-month RFS (%, 95% CI) | 67% (42-100) | 38% (15-92) |
| 12-month RFS (%, 95% CI) | 67% (42-100) | 38% (15-92) |
| . | CAR19-22 + NKTR-255 (n = 9) . | CAR19-22 control (n = 8) . |
|---|---|---|
| CR/CRi | 8 (89%) | 7 (88%) |
| MRD-negative | 8 (89%) | 6 (75%) |
| Progression/relapse | 3 (33%) | 5 (62%) |
| Consolidative HCT | 2 (23%) | 1 (13%) |
| 6-month RFS (%, 95% CI) | 67% (42-100) | 38% (15-92) |
| 12-month RFS (%, 95% CI) | 67% (42-100) | 38% (15-92) |
CRi, complete response with incomplete count recovery; RFS, relapse free survival; MRD, measurable residual disease.